Eugene C. Yi

Prof. Eugene C. Yi

Dept of Molecular Medicine and Biopharmaceutical Sciences, School of Medicine & Pharmacy, Seoul National University, Biomedical Science Building 305, 103 Daehakro, Jongro-gu, Seoul 03080, Korea
orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 November 2013 in Experimental & Molecular Medicine
Verified
Journal Article
Open access
PDF file
YLYong Yook Lee
Yong Yook Lee
HKHwang-Phill Kim
Hwang-Phill Kim
MKMin Jueng Kang
Min Jueng Kang
BCByoung-Kyu Cho
Byoung-Kyu Cho
SHSae-Won Han
Sae-Won Han
Eugene C. YiEugene C. Yi
Eugene C. Yi
Lapatinib, a dual inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) tyrosine kinases, has shown promising results as a growth inhibitor of HER2-positive cancer cells in vitro. However, similar to other EGFR-targeting drugs, acquired resistance to lapatinib by HER2-positive cancer cells remains a major clinical challenge. To elucidate resistance mechanisms to EGFR/HER2-targeting agents, we performed a systematic quantitative comparison of the phosphoproteome of lapatinib-resistant (LR) human gastric cancer cells (SNU216-LR) versus parental cells (SNU216) using a titanium dioxide (TiO2) phosphopeptide enrichment method and analysis with a Q-Exactive hybrid quadrupole-Orbitrap mass spectrometer. Biological network analysis of differentially expressed phosphoproteins revealed apparent constitutive activation of the MET-axis phosphatidylinositide 3-kinase (PI3K)/α-serine/threonine-protein kinase (AKT) and mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) signaling pathways in SNU216-LR. Inhibition of the PI3K/AKT and MAPK/ERK signaling pathways in SNU216-LR also leads to cell cycle arrest, confirming the biological network analysis. Lapatinib sensitivity was restored when cells were treated with several molecular targeting agents in combination with lapatinib. Thus, by integrating phosphoproteomic data, protein networks and effects of signaling pathway modulation on cell proliferation, we found that SNU216-LR maintains constitutive activation of the PI3K/AKT and MAPK/ERK pathways in a MET-dependent manner. These findings suggest that pathway activation is a key compensatory intracellular phospho-signaling event that may govern gastric cancer cell resistance to drug treatment.

1 December 2014 in Molecules and Cells
Verified
Journal Article
Open access
PDF file
YKYikwon Kim
Yikwon Kim
DHDohyun Han
Dohyun Han
HMHophil Min
Hophil Min
JJJonghwa Jin
Jonghwa Jin
Eugene C. YiEugene C. Yi
Eugene C. Yi
YKYoungsoo Kim
Youngsoo Kim
Yikwon Kim, Dohyun Han, Hophil Min, Jonghwa Jin, Eugene C. Yi, and Youngsoo Kim. Mol. Cells 2014;37:888-98. https://doi.org/10.14348/molcells.2014.0207

16 August 2014 in Diabetes
Verified
Journal Article
Closed access
PDF file
BKBo Kyung Koo
Bo Kyung Koo
SCSehyun Chae
Sehyun Chae
KKKristine M. Kim
Kristine M. Kim
MKMin Jueng Kang
Min Jueng Kang
EKEunhee G. Kim
Eunhee G. Kim
KPKyong Soo Park
Kyong Soo Park
Autoantibodies can facilitate diagnostic and therapeutic means for type 1 diabetes (T1DM). We profiled autoantibodies from serum samples of 16 T1DM patients, 16 type 2 diabetic (T2DM) patients, and 27 healthy control subjects with normal glucose tolerance (NGT) by using protein microarrays containing 9,480 proteins. Two novel autoantibodies, anti-EEF1A1 and anti-UBE2L3, were selected from microarrays followed by immunofluorescence staining of pancreas. We then tested the validity of the candidates by ELISA in two independent test cohorts: 1) 95 adults with T1DM, 49 with T2DM, 11 with latent autoimmune diabetes in adults (LADA), 20 with Graves disease, and 66 with NGT and 2) 33 children with T1DM and 34 healthy children. Concentrations of these autoantibodies were significantly higher in T1DM patients than in NGT and T2DM subjects (P < 0.01), which was also confirmed in the test cohort of children (P < 0.05). Prevalence of anti-EEF1A1 and anti-UBE2L3 antibodies was 29.5% and 35.8% in T1DM, respectively. Of note, 40.9% of T1DM patients who lack anti-GAD antibodies (GADA) had anti-EEF1A1 and/or anti-UBE2L3 antibodies. These were also detected in patients with fulminant T1DM but not LADA. Our approach identified autoantibodies that can provide a new dimension of information indicative of T1DM independent of GADA and new insights into diagnosis and classification of T1DM.

2 April 2013 in Proteomics
Verified
Journal Article
Closed access
PDF file
MKMin Jueng Kang
Min Jueng Kang
HKHwang‐Phill Kim
Hwang‐Phill Kim
KLKyeong‐Seob Lee
Kyeong‐Seob Lee
YYYoung‐Dong Yoo
Young‐Dong Yoo
YKYong‐Tae Kwon
Yong‐Tae Kwon
Eugene C. YiEugene C. Yi
Eugene C. Yi

15 September 2014 in Journal of Proteome Research
Verified
Journal Article
Closed access
MKMin Jueng Kang
Min Jueng Kang
YPYune-Jung Park
Yune-Jung Park
SYSungyong You
Sungyong You
SYSeung-Ah Yoo
Seung-Ah Yoo
SCSusanna Choi
Susanna Choi
WKWan-Uk Kim
Wan-Uk Kim

20 September 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
HLHa Yun Lee
Ha Yun Lee
EKEunhee G. Kim
Eunhee G. Kim
HJHye Ryeon Jung
Hye Ryeon Jung
JJJin Woo Jung
Jin Woo Jung
HKHan Byeol Kim
Han Byeol Kim
Eugene C. YiEugene C. Yi
Eugene C. Yi
Mass spectrometry-based spectral count has been a common choice of label-free proteome quantification due to the simplicity for the sample preparation and data generation. The discriminatory nature of spectral count in the MS data-dependent acquisition, however, inherently introduces the spectral count variation for low-abundance proteins in multiplicative LC-MS/MS analysis, which hampers sensitive proteome quantification. As many low-abundance proteins play important roles in cellular processes, deducing low-abundance proteins in a quantitatively reliable manner greatly expands the depth of biological insights. Here, we implemented the Moment Adjusted Imputation error model in the spectral count refinement as a post PLGEM-STN for improving sensitivity for quantitation of low-abundance proteins by reducing spectral count variability. The statistical framework, automated spectral count refinement by integrating the two statistical tools, was tested with LC-MS/MS datasets of MDA-MB468 breast cancer cells grown under normal and glucose deprivation conditions. We identified about 30% more quantifiable proteins that were found to be low-abundance proteins, which were initially filtered out by the PLGEM-STN analysis. This newly developed statistical framework provides a reliable abundance measurement of low-abundance proteins in the spectral count-based label-free proteome quantification and enabled us to detect low-abundance proteins that could be functionally important in cellular processes.